Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. patient registry
Show results for
Products
Services
Software
Applications

Companies

News
Downloads

Refine by
Date

  • Older

Patient Registry Articles & Analysis

23 news found

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

Baliga BIOS-03: Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry Timothy J. Stuhlmiller, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Al Musella, Santosh Kesari “I’m proud to present these analyses of real-world data and clinical ...

ByxCures


Evolution of ePROM: Advancements, Concerns, and the Way Forward

Evolution of ePROM: Advancements, Concerns, and the Way Forward

This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, so caregivers and clinicians can know about the patient’s health concerns outside the clinical setting. ...

ByJeeva Informatics Solutions Inc.


Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT

Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT

(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a ...

ByInari Medical


Recognizing 10 years of philanthropic support for prostate cancer research

Recognizing 10 years of philanthropic support for prostate cancer research

Lewis founded the Alberta Prostate Cancer Research Institute (APCaRI), an international collaborative network of prostate cancer scientists, physicians, healthcare employees, and patients. APCaRI’s mission is to accelerate the translation of prostate cancer research from the laboratory to the clinic to improve the lives of men with prostate cancer. Through APCaRI, the Lewis ...

ByNanostics Inc.


Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). ...

ByInari Medical


Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences

Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences

First, the in-hospital and 30-day results from the fully enrolled 800-patient US cohort of the FLASH registry will be presented at the TCT conference in Boston on September 18th. ...

ByInari Medical


Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment.

Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment.

Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...

ByLipella Pharmaceuticals Inc.


Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings

Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings

“We look forward to sharing updates at the National Kidney Foundation’s Spring Clinical Meetings, including the design of a prospective observational registry of patients treated with LUPKYNIS.” Presentations related to LUPKYNIS at the meetings include: Title: “The Efficacy of Voclosporin in Lupus Nephritis is Independent of Changes in ...

ByAurinia Pharmaceuticals Inc.


PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

Additional MBCC Poster Presentations Include: Posters will be available online for viewing during the duration of the conference and available in-person during the poster receptions on March 3rd and 4th The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients with DCIS ...

ByPreludeDx


Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...

ByIvantis, Inc.


Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

“Several studies have shown that even small amounts of visual field loss can lead to limitations in common activities such as driving, reading, and a patient’s ability to exercise or go outside the house. Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. ...

ByIvantis, Inc.


Healx pledges $25,000 to AKU Society patient registry campaign

Healx pledges $25,000 to AKU Society patient registry campaign

Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. ...

ByHealx Ltd.


Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...

ByIvantis, Inc.


Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy

Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy

Pittsburgh, PA – (April 30, 2021) – The Bladder Health Foundation announces the rollout of the first on-line patient registry for pelvic radiation cancer survivors. The online registry is located at www.radiationcystitis.com The Bladder Health Foundation, with support from Lipella Pharmaceuticals Inc., is promoting the awareness of ...

ByLipella Pharmaceuticals Inc.


Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition

Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition

Ataxia UK is the leading charity in the United Kingdom for people affected by ataxia - an umbrella term for a group of neurological disorders that target the nervous system and affect balance, coordination and speech. FARA (Friedreich’s Ataxia Research Alliance) is a non-profit organisation in the US, dedicated to supporting research into treatments and cures for Friedreich’s ataxia, ...

ByHealx Ltd.


Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

It was designed to demonstrate the safety and efficacy of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone, respectively. ...

ByIvantis, Inc.


Longenesis announces Curator platform for privacy-preserving data use for COVID-19 research

Longenesis announces Curator platform for privacy-preserving data use for COVID-19 research

It is a platform where clinical institutions and patient organizations are connected in consortiums with potential collaboration partners and study sponsors to initiate further cooperation. ...

ByLongenesis


Ivantis Recognized For Innovation, Excellence And Company Culture

Ivantis Recognized For Innovation, Excellence And Company Culture

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma ...

ByIvantis, Inc.


Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

The study was designed to demonstrate the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone. ...

ByIvantis, Inc.


GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. ...

ByGT Medical Technologies, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT